Related Experiment Video
Updated: May 11, 2026
08:54
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on
Beverly A Teicher1, Li Chen2, Dianne L Newton3
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Molecular Cancer Therapeutics
|February 19, 2026
Summary
CD248 (endosialin) is a promising therapeutic target for sarcomas and fibrotic diseases due to its selective expression in tumors. Research explores its role in cancer therapy, particularly for Ewing
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- CD248, also known as endosialin or TEM1, has emerged as a significant therapeutic target.
- Its function has been extensively studied over the past 30 years, revealing its potential in treating specific diseases.
- CD248 plays a role in tissue structure by connecting different cell types within a multi-protein complex.
Purpose of the Study:
- To review existing literature on CD248 (endosialin/TEM1) and its therapeutic potential.
- To examine the expression patterns of CD248 in various preclinical models and cell line collections.
- To highlight CD248 as a target for novel cancer therapies, especially for sarcomas and fibrotic diseases.
Main Methods:
- Literature review on CD248 function and therapeutic targeting.
- Analysis of CD248 expression in patient-derived xenografts and cell lines.
- Examination of data from large cell line collections like CCLE and GDSC-MGH-Sanger.
Main Results:
- CD248 is highly and selectively expressed in sarcomas.
- It is also found in pericytes within tumor and wound-healing vasculature.
- CD248 is overexpressed in several human solid tumors but largely absent in normal adult tissues.
Conclusions:
- CD248 (endosialin/TEM1) is a promising therapeutic target for sarcomas and fibrotic diseases.
- Its selective expression profile makes it a potentially safe target for radioimmunotherapy.
- Further exploration of CD248 in cancer therapy, particularly for Ewing's sarcoma, is warranted.
More Related Videos
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:41Non-Canonical Wnt Signaling Pathways
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:25Selectins
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...